The GPNMB Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the PaTu 8988t human pancreatic ductal adenocarcinoma cell line. This product provides a heterogeneous pool of cells with targeted disruption of the GPNMB gene, enabling loss-of-function studies without clonal selection. The polyclonal format preserves biological variability while ensuring robust reduction of gene expression across the population, making it suitable for downstream applications that require population-level analyses.
The PaTu 8988t host cell line is an epithelial pancreatic cancer model isolated from a primary pancreatic ductal adenocarcinoma. Characterized by an oncogenic KRAS mutation, this cell line recapitulates key features of pancreatic cancer biology, including deregulated proliferation, invasive potential, and aberrant signal transduction. Its widespread use in pancreatic cancer research establishes it as a relevant and well-characterized platform for investigating tumorigenic mechanisms and therapeutic interventions.
GPNMB encodes a transmembrane glycoprotein that promotes cell adhesion, migration, invasion, and proliferation, and modulates immune responses. Mechanistically, GPNMB engages integrins (??v??3, ??5??1), triggering FAK and Src activation, which stimulates MAPK/ERK and PI3K/AKT cascades. Upstream regulators include TGF-??, HIF1??, NF-??B, oncogenic KRAS, and STAT3, while downstream targets encompass ERK1/2, AKT, ??-catenin, MMP-2/9, and EMT-associated Snail and Slug. GPNMB interacts with CD44 and ADAM10, with ADAM10 mediating ectodomain shedding, and influences autophagy via LC3B and Beclin-1. This network positions GPNMB at the nexus of EMT, invasion, and survival signaling.
In the context of PaTu 8988t cells, GPNMB is particularly significant because its expression is driven by oncogenic KRAS, a hallmark of pancreatic ductal adenocarcinoma. The knockout model thus allows dissection of KRAS-dependent signaling outputs mediated through GPNMB, including enhanced migratory and invasive properties. By ablating GPNMB, researchers can probe the gene’s contribution to the aggressive phenotype of pancreatic cancer, assess its role in tumor-stroma crosstalk, and explore its impact on responses to standard-of-care chemotherapeutics, thereby illuminating potential therapeutic vulnerabilities.
This polyclonal knockout population is designed for investigating pancreatic cancer invasion, metastasis, and drug resistance. Typical experiments include Western blotting for GPNMB and phospho-ERK/AKT, scratch and Transwell migration assays, Matrigel invasion, immunofluorescence for EMT markers, flow cytometry for integrin surface expression, drug sensitivity profiling, RNA-seq transcriptomics, co-immunoprecipitation of GPNMB-integrin interactions, and phospho-kinase array screening. These approaches allow comprehensive functional characterization. For technical support or ordering, contact Ascent Research.
